idarubicin + mitoxantrone + cytarabine

idarubicin + mitoxantrone + cytarabine is an intensive chemotherapy induction regimen used for the treatment of newly diagnosed acute myeloid leukemia (AML). This specific combination, often referred to as a variation of the standard 3+7 regimen, consists of the anthracycline idarubicin, the anthraquinone mitoxantrone, and the antimetabolite cytarabine. Idarubicin and mitoxantrone function by intercalating into DNA and inhibiting topoisomerase II, leading to double-strand breaks and cell death. Cytarabine, a pyrimidine analog, is converted into cytarabine triphosphate, which competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA, thereby inhibiting DNA polymerase and halting DNA synthesis. This regimen is currently being utilized as a standard-of-care comparator in clinical trials conducted by Guangdong Provincial People's Hospital to evaluate the efficacy of novel triplet and doublet therapies like ABC-14 (azacitidine, venetoclax, and chidamide).

Other names

anthracyclines + anthraquinones3+7 standard induction therapyanthracyclines + anthraquinones-Guangdong Provincial People's Hospital-acute myeloid leukemia